Jonas Mattsson

List of Publications by Year in descending order

219 papers	4,736 citations	94433 37 h-index	138484 58 g-index
219 all docs	219 docs citations	219 times ranked	5272 citing authors

#	Article	IF	Citations
1	Bloodstream Infections and Outcomes Following Allogeneic Hematopoietic Cell Transplantation: A Single-Center Study. Transplantation and Cellular Therapy, 2022, 28, 50.e1-50.e8.	1.2	11
2	Antiâ€thymocyte globulin and postâ€transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts. European Journal of Haematology, 2022, 108, 61-72.	2.2	9
3	Allogeneic hematopoietic stem cell transplantation in patients with therapyâ€related hematologic malignancies developing after multiple myeloma. European Journal of Haematology, 2022, 108, 430-436.	2.2	2
4	A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells <i>in vitro</i> and <i>in vivo</i>. Haematologica, 2022, 107, 1786-1795.	3.5	5
5	Improving Safety and Outcomes After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience. Transplantation and Cellular Therapy, 2022, 28, 265.e1-265.e9.	1.2	6
6	Letermovir Prophylaxis for Cytomegalovirus Reactivation in Allogeneic Hematopoietic Cell Transplant Recipients: A Single Centre Experience. Transplantation and Cellular Therapy, 2022, 28, S87.	1.2	0
7	Frailty Scale for Outcome Predictions in Hematopoietic Cell Transplanted Adults. Transplantation and Cellular Therapy, 2022, 28, S439-S440.	1.2	0
8	Chronic kidney disease, survival and graft-versus-host-disease-free/relapse-free survival in recipients of allogeneic hematopoietic stem cell transplant. CKJ: Clinical Kidney Journal, 2022, 15, 1583-1592.	2.9	2
9	Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment. Seminars in Cancer Biology, 2022, 86, 207-223.	9.6	35
10	The 17â€gene stemness score associates with relapse risk and longâ€term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia. EJHaem, 2022, 3, 873-884.	1.0	2
11	Relationship between certain HLA alleles and the risk of cytomegalovirus reactivation following allogeneic hematopoietic stem cell transplantation. Transplant Infectious Disease, 2022, 24, .	1.7	2
12	Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress. , 2022, 10, e004458.		18
13	Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality. OncoImmunology, 2022, 11, .	4.6	9
14	Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Acta Haematologica, 2021, 144, 66-73.	1.4	11
15	Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 60-69.	2.4	26
16	Effect of donor age and kinship on outcomes in haplo-identical stem cell transplantation may be modulated by GVHD prophylaxis strategies. Bone Marrow Transplantation, 2021, 56, 689-691.	2.4	1
17	Clinical prevalence and outcome of cardiovascular events in the first 100 days postallogeneic hematopoietic stem cell transplant. European Journal of Haematology, 2021, 106, 32-39.	2.2	16
18	Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy. Stem Cell Reviews and Reports, 2021, 17, 63-70.	3.8	5

#	Article	IF	Citations
19	Oral mucositis after tacrolimus/sirolimus or cyclosporine/methotrexate as graftâ€versusâ€host disease prophylaxis. Oral Diseases, 2021, 27, 1217-1225.	3.0	4
20	Prolactin, a potential biomarker for chronic GVHD activity. European Journal of Haematology, 2021, 106, 158-164.	2.2	2
21	Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease. European Journal of Health Economics, 2021, 22, 169-180.	2.8	9
22	Fresh vs. frozen allogeneic peripheral blood stem cell grafts: A successful timely option. American Journal of Hematology, 2021, 96, 179-187.	4.1	23
23	Outcomes of adult patients with acute myeloid leukemia and unsuccessful cytogenetic analysis undergoing allogeneic hematopoietic stem cell transplantation. Hematology/ Oncology and Stem Cell Therapy, 2021, 14, 134-140.	0.9	1
24	Vitamin D levels and busulphan kinetics in patients undergoing hematopoietic stem cell transplantation, a multicenter study. Bone Marrow Transplantation, 2021, 56, 807-817.	2.4	0
25	Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level. Annals of Hematology, 2021, 100, 789-798.	1.8	5
26	Predictors of outcomes of therapy-related acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Hematology/ Oncology and Stem Cell Therapy, 2021, , .	0.9	3
27	Moderate-severe grade of chronic graft versus host disease and younger age (less than 45 years old) are risk factors for avascular necrosis in adult patients undergoing allogeneic hematopoietic cell transplantation. Annals of Hematology, 2021, 100, 1311-1319.	1.8	2
28	Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Bone Marrow Transplantation, 2021, 56, 1908-1918.	2.4	10
29	Mesothelin-Specific CAR T Cells Target Ovarian Cancer. Cancer Research, 2021, 81, 3022-3035.	0.9	45
30	Experience Using Anti-Thymocyte Globulin With Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 428.e1-428.e9.	1.2	11
31	Efficacy and cost analysis of eltrombopag in thrombocytopenia and poor graft function post allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 2471-2476.	2.4	5
32	Pretransplant bone marrow cellularity and blood count recovery are not associated with relapse or survival risk following allogeneic stem cell transplant for AML in CR. European Journal of Haematology, 2021, 107, 354-363.	2.2	1
33	Effect of preâ€transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis. European Journal of Haematology, 2021, 107, 517-528.	2.2	2
34	Association of Factors Influencing Selection of Upfront Hematopoietic Cell Transplantation versus Nontransplantation Therapies in Myelofibrosis. Transplantation and Cellular Therapy, 2021, 27, 600.e1-600.e8.	1.2	5
35	Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections. Leukemia and Lymphoma, 2021, 62, 3373-3383.	1.3	12
36	Refined hepatic grading system in chronic graftâ€versusâ€host disease improves prognostic risk stratification of longâ€term outcomes. European Journal of Haematology, 2021, 106, 508-519.	2.2	1

#	Article	IF	Citations
37	Update of Multicenter, Retrospective Evaluation of Overall Response and Failure Free Survival Following Ruxolitinib Therapy for Heavily Pre-Treated Chronic Gvhd Patients with Steroid-Failure: A Proposal of Risk Score Model for Failure-Free Survival. Blood, 2021, 138, 3905-3905.	1.4	0
38	Single Centre, Retrospective Analysis of Extracorporeal Photopheresis (ECP) Therapy in the Patients Who Are Heavily Pre-Treated for Steroid Resistant Chronic Graft-Versus-Host Disease (GVHD). Blood, 2021, 138, 1806-1806.	1.4	0
39	Propensity Score Matching Analysis Comparing Extracorporeal Photopheresis (ECP) Vs Best Available Therapy in Third Line or Later Treatment of Chronic Graft-Versus-Host Disease (cGVHD). Blood, 2021, 138, 3896-3896.	1.4	0
40	A Novel CD34-Specific T-Cell Engager Efficiently Depletes Stem Cells and Acute Myeloid Leukemia Cells in Vitro and In Vivo. Blood, 2021, 138, 2861-2861.	1.4	1
41	Frailty Scale for Outcome Predictions in Hematopoietic Cell Transplanted Adults. Blood, 2021, 138, 110-110.	1.4	0
42	Outcomes of patients diagnosed with chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation: Results from a tertiary care center. Hematology/ Oncology and Stem Cell Therapy, 2021, , .	0.9	0
43	Reduced Risk of Sinusoidal Obstruction Syndrome of the Liver after Busulfanâ€Cyclophosphamide Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation. Clinical and Translational Science, 2020, 13, 293-300.	3.1	10
44	Impact of CD34+ cell dose on reduced intensity conditioning regimen haploidentical hematopoietic stem cell transplantation. European Journal of Haematology, 2020, 104, 36-45.	2.2	7
45	Treatment of radiculomyelopathy in two patients with placenta-derived decidua stromal cells. International Journal of Hematology, 2020, 111, 591-594.	1.6	4
46	Allogeneic stem cell transplant in myelodysplastic syndromeâ€factors impacting survival. European Journal of Haematology, 2020, 104, 116-124.	2.2	5
47	Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination. OncoImmunology, 2020, 9, 1792058.	4.6	30
48	Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with CD11c+ Expression in Tumor. Advances in Therapy, 2020, 37, 5023-5031.	2.9	6
49	Patient-reported symptom burden of chronic graft versus host disease: a systematic literature review. Expert Review of Hematology, 2020, 13, 1119-1130.	2.2	1
50	Profound Functional Suppression of Tumor-Infiltrating T-Cells in Ovarian Cancer Patients Can Be Reversed Using PD-1-Blocking Antibodies or DARPinÂ® Proteins. Journal of Immunology Research, 2020, 2020, 1-12.	2.2	8
51	High incidence but low mortality of EBV-reactivation and PTLD after alloHCT using ATG and PTCy for GVHD prophylaxis. Leukemia and Lymphoma, 2020, 61, 3198-3208.	1.3	9
52	Diagnostic disagreement between clinical standard histopathologicalâ€and retrospective assessment of histopathologyâ€based gastrointestinal graftâ€versusâ€host disease in children. Pediatric Transplantation, 2020, 24, e13824.	1.0	2
53	Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation. Annals of Hematology, 2020, 99, 1377-1387.	1.8	15
54	Less Is More: Superior Graft-versus-Host Disease-Free/Relapse-Free Survival with Reduced-Intensity Conditioning and Dual T Cell Depletion in Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation, 2020, 26, 1511-1519.	2.0	6

#	Article	IF	Citations
55	Posttransplantation Lymphoproliferative Disease Treated by Retransplantation. Case Reports in Immunology, 2020, 2020, 1-4.	0.4	2
56	Outcomes of therapyâ€related acute lymphoblastic leukemia in adults after allogeneic stem cell transplantation. European Journal of Haematology, 2020, 105, 24-29.	2.2	5
57	The Effect of Donor Age on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, S282.	2.0	0
58	Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD. Bone Marrow Transplantation, 2020, 55, 1773-1783.	2.4	35
59	Multicenter evaluation of parametric response mapping as an indicator of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. American Journal of Transplantation, 2020, 20, 2198-2205.	4.7	24
60	Incidence, Outcomes and Predictors of Acute Kidney Injury Post Allogeneic Stem Cell Transplant. Blood, 2020, 136, 16-17.	1.4	5
61	Epsteinâ€Barr virus associated postâ€transplant lymphoproliferative disorder mimicking acute graft versus host disease. European Journal of Haematology, 2019, 103, 519-522.	2.2	2
62	Granulocyte transfusions could benefit patients with severe oral mucositis after allogeneic hematopoietic stem cell transplantation. Vox Sanguinis, 2019, 114, 769-777.	1.5	4
63	Reducedâ€intensity conditioning allogeneic transplant with dual Tâ€cell depletion in myelofibrosis. European Journal of Haematology, 2019, 103, 597-606.	2.2	9
64	The Metabolic Profile of Tumor and Virally Infected Cells Shapes Their Microenvironment Counteracting T Cell Immunity. Frontiers in Immunology, 2019, 10, 2309.	4.8	19
65	Reduced intensity allogeneic stem cell transplant with antiâ€thymocyte globulin and postâ€transplant cyclophosphamide in acute myeloid leukemia. European Journal of Haematology, 2019, 103, 510-518.	2.2	19
66	Impact of central nervous system involvement in AML on outcomes after allotransplant and utility of pretransplant cerebrospinal fluid assessment. European Journal of Haematology, 2019, 103, 483-490.	2.2	10
67	Metabolic regulation of CAR T cell function by the hypoxic microenvironment in solid tumors. Immunotherapy, 2019, 11, 335-345.	2.0	42
68	Effect of Graft-versus-Host Disease Prophylaxis Regimens on T and B Cell Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1260-1268.	2.0	21
69	A Novel Method to Evaluate Outcomes of Chronic Graft Vs Host Disease by Using National Population-Based Real-World Data. Biology of Blood and Marrow Transplantation, 2019, 25, S223.	2.0	1
70	Long-Term Follow-Up of a Pilot Study Using Placenta-Derived Decidua Stromal Cells for Severe Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2019, 25, 1965-1969.	2.0	14
71	Combination of the Centre for International Blood and Marrow Transplant Registry Risk Score and the Global Severity Score Enhances Prognostic Risk Stratification in Patients Receiving Frontline Therapy for Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2019, 25, 1761-1769.	2.0	1
72	Higher response rates in patients with severe chronic skin graft-versus-host disease treated with extracorporeal photopheresis. Central-European Journal of Immunology, 2019, 44, 84-91.	1.2	6

#	Article	IF	Citations
73	Facing the future: challenges and opportunities in adoptive T cell therapy in cancer. Expert Opinion on Biological Therapy, 2019, 19, 811-827.	3.1	27
74	The importance of graft cell composition in outcome after allogeneic stem cell transplantation in patients with malignant disease. Clinical Transplantation, 2019, 33, e13537.	1.6	5
75	Long Term Follow-up of a Pilot Study Using Placenta-Derived Decidua Stromal Cells for Severe Acute Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2019, 25, S247.	2.0	0
76	A systematic literature review of incidence, mortality, and relapse of patients diagnosed with chronic graft versus host disease. Expert Review of Hematology, 2019, 12, 311-323.	2.2	18
77	Humanistic burden of patients with chronic graft-versus-host disease - systematic literature review of health-related quality of life and functional status. Expert Review of Hematology, 2019, 12, 295-309.	2.2	11
78	T-cell frequencies of CD8+ Î³Î´ and CD27+ Î³Î´ cells in the stem cell graft predict the outcome after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2019, 54, 1562-1574.	2.4	17
79	Individualization of Hematopoietic Stem Cell Transplantation Using Alpha/Beta T-Cell Depletion. Frontiers in Immunology, 2019, 10, 189.	4.8	10
80	The Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Inherited Diseases Is Influenced by HLA Match, Year of Transplantation, and Immunized Female Donor. Transplantation, 2019, 103, 1247-1252.	1.0	3
81	Pre-formulation investigations for establishing a protocol for treosulfan handling and activation. Pharmaceutical Development and Technology, 2019, 24, 639-648.	2.4	0
82	Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review. Biology of Blood and Marrow Transplantation, 2019, 25, 720-727.	2.0	47
83	Pilot Study on Frailty and Functionality on Routine Clinical Assessment in Allogeneichematopoietic Cell Transplantation to Predict Outcomes. Blood, 2019, 134, 380-380.	1.4	3
84	Allogeneic Stem Cell Transplantation Has Limited Benefit in Older Patients with Mixed Phenotype Acute Leukemia. Blood, 2019, 134, 5725-5725.	1.4	1
85	Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation for Myeloid Malignancies Using Post-transplantation Cyclophosphamide and Anti-thymocyte Globulin as Graft-versus-Host Disease Prophylaxis. Clinical Hematology International, 2019, 1, 105-113.	1.7	18
86	Dual T-Cell Depletion with a Very Low Dose of ATG and Ptcy Provides an Effective Control of Acute Gvhd in PBSC RIC Allo-HSCT. Blood, 2019, 134, 5669-5669.	1.4	0
87	Largest Single Center Experience Using Dual T-Cell Depletion with ATG and Ptcy for Gvhd Prophylaxis in Peripheral Blood RIC Allo-HSCT. Blood, 2019, 134, 3344-3344.	1.4	0
88	Patient Age and Donor HLA Matching Can Stratify Allogeneic Hematopoietic Cell Transplantation (HCT) Patients into Prognostic Groups: A Collaborative Study. Blood, 2019, 134, 3341-3341.	1.4	0
89	The 17-Gene Leukemic Stemess Score Can Predict Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. Blood, 2019, 134, 3299-3299.	1.4	0
90	Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning. Blood, 2019, 134, 4590-4590.	1.4	0

#	Article	IF	Citations
91	Outcomes of Therapy Related Acute Lymphoblastic Leukemia in Adults after Allogeneic Stem Cell Transplantation - Twenty-Year Experience from a Tertiary Care Center. Blood, 2019, 134, 5717-5717.	1.4	0
92	Predictors of Outcomes in Adult Patients with Therapy Related Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation - Twenty Year Experience from a Tertiary Care Centre. Blood, 2019, 134, 5737-5737.	1.4	0
93	Impact of Hematopoeitic Cell Transplantation-Co-Morbidity Index (HCT-CI) and Its Individual Components on Allogeneic Transplant Outcomes. Blood, 2019, 134, 5722-5722.	1.4	0
94	No Impact of Donor's Age-Related Clonal Hematopoiesis (ARCH) Observed on Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Result from Bar-Coded Error Corrected Sequencing in 33 Gene Mutations on 372 Pairs of Donor and Recipient. Blood, 2019, 134, 4514-4514.	1.4	0
95	Improved Gvhd Free, Relapse Free Survival Using Dual T-Cell Depletion with ATG and Ptcy in Matched Unrelated Donor RIC Allo-HSCT. Blood, 2019, 134, 4594-4594.	1.4	0
96	Norovirus causing severe gastrointestinal disease following allogeneic hematopoietic stem cell transplantation: A retrospective analysis. Transplant Infectious Disease, 2018, 20, e12847.	1.7	10
97	Risk Factors for Severe Acute Graft-versus-Host Disease in Donor Graft Composition. Biology of Blood and Marrow Transplantation, 2018, 24, 467-477.	2.0	13
98	Long-term outcome in patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. International Journal of Hematology, 2018, 107, 478-485.	1.6	11
99	The effect of N-acetyl-l-cysteine (NAC) on liver toxicity and clinical outcome after hematopoietic stem cell transplantation. Scientific Reports, 2018, 8, 8293.	3.3	11
100	Media evaluation for production and expansion of anti-CD19 chimeric antigen receptor T cells. Cytotherapy, 2018, 20, 941-951.	0.7	16
101	Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based Decisions. Biology of Blood and Marrow Transplantation, 2017, 23, 677-683.	2.0	12
102	A Preliminary Report: Radical Surgery and Stem Cell Transplantation for the Treatment of Patients With Pancreatic Cancer. Journal of Immunotherapy, 2017, 40, 132-139.	2.4	5
103	No effect of <scp>HLA</scp>â€C mismatch after allogeneic hematopoietic stem cell transplantation with unrelated donors and Tâ€cell depletion in patients with hematological malignancies. Clinical Transplantation, 2017, 31, e13012.	1.6	0
104	Toxicological effects of fludarabine and treosulfan conditioning before allogeneic stem-cell transplantation. International Journal of Hematology, 2017, 106, 471-475.	1.6	8
105	Combining Flow and Mass Cytometry in the Search for Biomarkers in Chronic Graft-versus-Host Disease. Frontiers in Immunology, 2017, 8, 717.	4.8	37
106	Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway. PLoS ONE, 2017, 12, e0187294.	2.5	17
107	Characterization of infiltrating lymphocytes in human benign and malignant prostate tissue. Oncotarget, 2017, 8, 60257-60269.	1.8	12
108	Donor Cell Composition and Reactivity Predict Risk of Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Immunology Research, 2016, 2016, 1-11.	2.2	13

#	Article	IF	Citations
109	Long-Term Stable Mixed Chimerism after Hematopoietic Stem Cell Transplantation in Patients with Non-Malignant Disease, Shall We Be Tolerant?. PLoS ONE, 2016, 11, e0154737.	2.5	23
110	Improved overall survival for pediatric patients undergoing allogeneic hematopoietic stem cell transplantation â€“ A comparison of the last two decades. Pediatric Transplantation, 2016, 20, 667-674.	1.0	26
111	Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer. Biology of Blood and Marrow Transplantation, 2016, 22, S423-S424.	2.0	0
112	Placenta-Derived Decidual Stromal Cells for Treatment of Severe Acute Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2016, 22, S48.	2.0	0
113	Identifying Cellular Subsets Diagnostic for Severity and Organ Specific Chronic GVHD. Biology of Blood and Marrow Transplantation, 2016, 22, S415.	2.0	0
114	A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation. Haematologica, 2016, 101, 1417-1425.	3.5	61
115	Risk Factors for Invasive Mold Infections and Implications for Choice of Prophylaxis after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1684-1689.	2.0	12
116	Community Acquired Respiratory Viral Infections (CARV) in Patients with Acute Leukemia and Hematopoietic Stem Cell Transplant (HSCT) Recipients. Biology of Blood and Marrow Transplantation, 2016, 22, S178.	2.0	0
117	Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer. Biology of Blood and Marrow Transplantation, 2016, 22, 676-681.	2.0	9
118	Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes. Oncotarget, 2016, 7, 23581-23593.	1.8	35
119	Risks and Benefits of Sex-Mismatched Hematopoietic Cell Transplantation Differ By Conditioning Strategy. Biology of Blood and Marrow Transplantation, 2015, 21, S340-S341.	2.0	0
120	An Increasing Severity of Chronic GvHD Is Associated to an Activated and Cytotoxic T Cell Mediated Immune-Phenotype. Biology of Blood and Marrow Transplantation, 2015, 21, S351.	2.0	0
121	Quality of the hematopoietic stem cell graft affects the clinical outcome of allogeneic stem cell transplantation. Transfusion, 2015, 55, 2339-2350.	1.6	23
122	Decidual Stromal Cells As Treatment for Acute Graft Versus Host Disease. Biology of Blood and Marrow Transplantation, 2015, 21, S349-S350.	2.0	0
123	HLA-C Mismatch without Impact on Outcome after Allogeneic HSCT. Biology of Blood and Marrow Transplantation, 2015, 21, S160.	2.0	0
124	Long-Term Stable Mixed Chimerism in Patients Undergoing HSCT for Non-Malignant Disorders. Biology of Blood and Marrow Transplantation, 2015, 21, S182-S183.	2.0	0
125	Effect of Total Nucleated and CD34+ Cell Dose on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 889-893.	2.0	106
126	Placenta-Derived Decidual Stromal Cells for Graft-Versus-Host Disease, Hemorrhaging, and Toxicity after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, S149.	2.0	6

#	Article	IF	Citations
127	Reply to: Transient Grades Three to Four Acute Hepatitis Is a Common Complication of Rabbit Antithymocyte Globulin (Thymoglobulin) Administered before Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1145-1146.	2.0	1
128	Transplanted Bone Marrow-Derived Cells Contribute to Human Adipogenesis. Cell Metabolism, 2015, 22, 408-417.	16.2	75
129	General health, symptom occurrence, and self-efficacy in adult survivors after allogeneic hematopoietic stem cell transplantation: a cross-sectional comparison between hospital care and home care. Supportive Care in Cancer, 2015, 23, 1273-1283.	2.2	17
130	Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy. Haematologica, 2015, 100, 1477-1485.	3.5	41
131	Home care during neutropenia after allogeneic hematopoietic stem cell transplantation in children and adolescents is safe and may be more advantageous than isolation in hospital. Pediatric Transplantation, 2014, 18, 398-404.	1.0	9
132	Novel method to characterize immune cells from human prostate tissue. Prostate, 2014, 74, 1391-1399.	2.3	10
133	Comparison of Algorithms for Oral Busulphan Area Under the Concentrationâ€“Time Curve Limited Sampling Estimate. Clinical Drug Investigation, 2014, 34, 43-52.	2.2	5
134	T-Cell Receptor Excision Circle Levels After Allogeneic Stem Cell Transplantation Are Predictive of Relapse in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Stem Cells and Development, 2014, 23, 1559-1567.	2.1	8
135	Improved Survival with Ursodeoxycholic Acid Prophylaxis in Allogeneic Stem Cell Transplantation: Long-Term Follow-Up of a Randomized Study. Biology of Blood and Marrow Transplantation, 2014, 20, 135-138.	2.0	58
136	Reduced IL-7 Responsiveness Defined by Signal Transducer and Activator of Transcription 5 Phosphorylation in T Cells May Be a Marker for Increased Risk of Developing Cytomegalovirus Disease in Patients after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 128-132.	2.0	5
137	Analysis of Donor and Recipient ABO Incompatibility and Antibody-Associated Complications after Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning. Biology of Blood and Marrow Transplantation, 2014, 20, 264-271.	2.0	41
138	Expanded umbilical cord blood T cells used as donor lymphocyte infusions after umbilical cord blood transplantation. Cytotherapy, 2014, 16, 1528-1536.	0.7	15
139	Second Solid Cancers after Allogeneic Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning. Biology of Blood and Marrow Transplantation, 2014, 20, 1777-1784.	2.0	50
140	Posaconazole Concentrations in Human Tissues after Allogeneic Stem Cell Transplantation. Antimicrobial Agents and Chemotherapy, 2014, 58, 4941-4943.	3.2	19
141	Varicella-Zoster Reactivation after Allogeneic Stem Cell Transplantation without Routine Prophylaxisâ€”The Incidence Remains High. Biology of Blood and Marrow Transplantation, 2014, 20, 1646-1649.	2.0	29
142	Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica, 2014, 99, 346-352.	3.5	153
143	Allogeneic Hematopoietic Cell Transplantation for GATA2 Deficiency in a Patient With Disseminated Human Papillomavirus Disease. Transplantation, 2014, 98, e95-e96.	1.0	13
144	Cyclophosphamide Alters the Gene Expression Profile in Patients Treated with High Doses Prior to Stem Cell Transplantation. PLoS ONE, 2014, 9, e86619.	2.5	10

#	Article	IF	Citations
145	Risks and Benefits of Sex-Mismatched Hematopoietic Cell Transplantation Differ By Conditioning Intensity. Blood, 2014, 124, 2537-2537.	1.4	0
146	Busulphan Metabolism Via Flavin-Containing Monooxygenase 3 (FMO3) Can Explain Several Interactions with Other Drugs. Blood, 2014, 124, 1150-1150.	1.4	0
147	Systems level immune response analysis and personalized medicine. Expert Review of Clinical Immunology, 2013, 9, 307-317.	3.0	8
148	Many Days at Home during Neutropenia after Allogeneic Hematopoietic Stem Cell Transplantation Correlates with Low Incidence of Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2013, 19, 314-320.	2.0	22
149	Chimerism Patterns of Long-Term Stable Mixed Chimeras Posthematopoietic Stem Cell Transplantation in Patients with Nonmalignant Diseases: Follow-Up of Long-Term Stable Mixed Chimerism Patients. Biology of Blood and Marrow Transplantation, 2013, 19, 838-844.	2.0	34
150	Fetal Membrane Cells for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease. Stem Cells, 2013, 31, 592-601.	3.2	84
151	Hospital care or home care after allogeneic hematopoietic stem cell transplantation â€“ Patients' experiences of care and support. European Journal of Oncology Nursing, 2013, 17, 389-395.	2.1	20
152	Cord Blood T Cells Cultured With IL-7 in Addition to IL-2 Exhibit a Higher Degree of Polyfunctionality and Superior Proliferation Potential. Journal of Immunotherapy, 2013, 36, 432-441.	2.4	12
153	A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning <scp>HSCT</scp> with unrelated donors. Clinical Transplantation, 2013, 27, E368-74.	1.6	50
154	Chimerism and use of mesenchymal stem cells in umbilical cord blood transplantation. Chimerism, 2013, 4, 34-35.	0.7	1
155	Graft Failure In Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 4559-4559.	1.4	0
156	Rapid Salvage Treatment With Virus-Specific T Cells for Therapy-Resistant Disease. Clinical Infectious Diseases, 2012, 55, 1064-1073.	5.8	116
157	Update on viral infections in lung transplantation. Current Opinion in Pulmonary Medicine, 2012, 18, 264-270.	2.6	22
158	Factors With an Impact on Chimerism Development and Long-Term Survival After Umbilical Cord Blood Transplantation. Transplantation, 2012, 94, 1066-1074.	1.0	20
159	Treatment with mesenchymal stromal cells is a risk factor for pneumoniaâ€related death after allogeneic hematopoietic stem cell transplantation. European Journal of Haematology, 2012, 89, 220-227.	2.2	69
160	Effects of different serum-levels of ATG after unrelated donor umbilical cord blood transplantation. Transplant Immunology, 2012, 27, 59-62.	1.2	24
161	Major surgery in a neutropenic patient undergoing allogeneic stem cell transplantation for high risk myelofibrosis. International Journal of Hematology, 2012, 96, 798-800.	1.6	2
162	Mesenchymal Stem Cells Inhibit Thymic Reconstitution After Allogeneic Cord Blood Transplantation. Stem Cells and Development, 2012, 21, 1409-1417.	2.1	26

#	Article	IF	Citations
163	Thymic function after allogeneic stem cell transplantation is dependent on graft source and predictive of long term survival. Clinical Immunology, 2012, 142, 343-350.	3.2	35
164	Expansion of T-cells from the cord blood graft as a predictive tool for complications and outcome of cord blood transplantation. Clinical Immunology, 2012, 143, 134-144.	3.2	3
165	Donor Lymphocyte Infusion May Reduce the Incidence of Bronchiolitis Obliterans after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1214-1221.	2.0	12
166	Improved Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Recent Years. A Single-Center Study. Biology of Blood and Marrow Transplantation, 2011, 17, 1688-1697.	2.0	131
167	Immune modulation to prevent antibody-mediated rejection after allogeneic hematopoietic stem cell transplantation. Transplant Immunology, 2011, 25, 153-158.	1.2	22
168	Second allogeneic hematopoietic stem cell transplantation: a treatment for graft failure. Clinical Transplantation, 2011, 25, E68-E76.	1.6	37
169	Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders. European Journal of Haematology, 2011, 87, 503-509.	2.2	24
170	In vitroorin vivoexpansion before adoptive T-cell therapy?. Immunotherapy, 2011, 3, 131-133.	2.0	0
171	Improved Survival with Ursodeoxycholic Acid Prophylaxis in Allogeneic Stem Cell Transplantation: Long-Term Follow-up of a Randomized Study of the Nordic Bone Marrow Transplantation Group. Blood, 2011, 118, 488-488.	1.4	0
172	Granulocyte Colony-Stimulating Factor Induced Acute and Chronic Graft-Versus-Host Disease. Transplantation, 2010, 90, 1022-1029.	1.0	29
173	Clinical Expansion of Cord Blood-derived T Cells for Use as Donor Lymphocyte Infusion After Cord Blood Transplantation. Journal of Immunotherapy, 2010, 33, 96-105.	2.4	29
174	A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation. Cancer Immunology, Immunotherapy, 2010, 59, 473-477.	4.2	74
175	C-reactive protein levels before reduced-intensity conditioning predict outcome after allogeneic stem cell transplantation. International Journal of Hematology, 2010, 92, 161-167.	1.6	13
176	GVHD prophylaxis using lowâ€dose cyclosporine improves survival in leukaemic recipients of HLAâ€identical sibling transplants. European Journal of Haematology, 2010, 84, 323-331.	2.2	14
177	Stable mixed double donor chimerism - Absence of war doesn't necessarily mean peace. Chimerism, 2010, 1, 64-65.	0.7	3
178	Leukemia Lineage-Specific Chimerism Analysis andÂMolecular Monitoring Improve Outcome of Donor Lymphocyte Infusions. Biology of Blood and Marrow Transplantation, 2010, 16, 1728-1737.	2.0	25
179	Stable mixed donorâ€“donor chimerism after double cord blood transplantation. International Journal of Hematology, 2009, 90, 526-531.	1.6	15
180	Increased Frequency and Responsiveness of PSA-Specific T Cells After Allogeneic Hematopoetic Stem-Cell Transplantation. Transplantation, 2009, 87, 467-472.	1.0	2

#	Article	IF	Citations
181	Respiratory Syncytial Virus Infection in Recipients of Allogeneic Stem-Cell Transplantation: A Retrospective Study of the Incidence, Clinical Features, and Outcome. Transplantation, 2009, 88, 1222-1226.	1.0	83
182	Norovirus Infections in Patients with Hematological Diseases and After Stem Cell Transplantation; Epidemiological and Clinical Aspects.. Blood, 2009, 114, 2661-2661.	1.4	0
183	Genomic tissue typing and optimal antithymocyte globuline dose using unrelated donors results in similar survival and relapse as HLA-identical siblings in haematopoietic stem-cell transplantation for leukaemia. European Journal of Haematology, 2008, 80, 419-428.	2.2	16
184	Graft Failure after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 165-170.	2.0	162
185	Case-Control Comparison of At-Home and Hospital Care for Allogeneic Hematopoietic Stem-Cell Transplantation: The Role of Oral Nutrition. Transplantation, 2008, 85, 1000-1007.	1.0	37
186	Novel Antibodies to the Donor Stem Cell Population CD34+/VEGFR-2+ Are Associated With Rejection After Hematopoietic Stem Cell Transplantation. Transplantation, 2008, 86, 686-696.	1.0	19
187	Recent progress in allogeneic stem cell transplantation. Current Opinion in Molecular Therapeutics, 2008, 10, 343-9.	2.8	11
188	Major ABO Blood Group Mismatch Increases the Risk for Graft Failure after Unrelated Donor Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2007, 13, 675-682.	2.0	68
189	Hemorrhagic cystitis: a retrospective singleâ€center survey. Clinical Transplantation, 2007, 21, 659-667.	1.6	59
190	Prospecitve Quantitative PCR Monitoring of Allogeneic Stem Cell Transplant (SCT) Patients at High Risk for EBV Associated PTLD.. Blood, 2007, 110, 2969-2969.	1.4	0
191	Allogeneic Hematopoietic Stem Cell Transplantation for Inherited Disorders: Experience in a Single Center. Transplantation, 2006, 81, 718-725.	1.0	59
192	Unrelated Versus Related Allogeneic Stem Cell Transplantation After Reduced Intensity Conditioning. Transplantation, 2006, 82, 913-919.	1.0	50
193	Decreasing mortality rate in early pneumonia following hematopoietic stem cell transplantation. Scandinavian Journal of Infectious Diseases, 2006, 38, 970-976.	1.5	28
194	Decreased Serum Levels of Clara Cell Secretory Protein (CC16) Are Associated with Bronchiolitis Obliterans and May Permit Early Diagnosis in Patients after Allogeneic Stem-Cell Transplantation. Transplantation, 2005, 79, 1411-1416.	1.0	34
195	Molecular monitoring of T-cell chimerism early after allogeneic stem cell transplantation may predict the occurrence of acute GVHD grades II-IV. Clinical Transplantation, 2005, 19, 346-349.	1.6	16
196	Increased gene expression of chemokine receptors is correlated with acute graft-versus-host disease after allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation, 2005, 11, 280-287.	2.0	37
197	Identification of Maternal Hematopoietic Cells in a 2nd-Trimester Fetus. Fetal Diagnosis and Therapy, 2005, 20, 355-358.	1.4	22
198	Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. Biology of Blood and Marrow Transplantation, 2004, 10, 195-203.	2.0	53

#	Article	IF	Citations
199	Allogenic stem cell transplantation for nonmalignant disorders using matched unrelated donors. Biology of Blood and Marrow Transplantation, 2004, 10, 877-882.	2.0	19
200	A Comparison of Nonmyeloablative and Reduced-Intensity Conditioning for Allogeneic Stem-Cell Transplantation. Transplantation, 2004, 78, 1014-1020.	1.0	59
201	Dose Study of Thymoglobulin During Conditioning for Unrelated Donor Allogeneic Stem-Cell Transplantation. Transplantation, 2004, 78, 122-127.	1.0	153
202	Increased immune transcript levels are correlated with acute graft-versus-host disease and cytomegalovirus response after allogeneic stem cell transplantation. Transplantation, 2004, 77, 195-200.	1.0	9
203	Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation, 2004, 78, 122-7.	1.0	109
204	Serum levels of cytokines correlate to donor chimerism and acute graft-vs.-host disease after haematopoietic stem cell transplantation. European Journal of Haematology, 2003, 70, 384-391.	2.2	47
205	Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia. British Journal of Haematology, 2003, 122, 788-794.	2.5	42
206	Liver transplantation followed by adjuvant nonmyeloablative hemopoietic stem cell transplantation for advanced primary liver cancer in humans1. Transplantation, 2003, 75, 1061-1066.	1.0	18
207	Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation. Blood, 2003, 101, 469-472.	1.4	47
208	Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 2002, 8, 674-682.	2.0	88
209	Prenatal T-cell reconstitution after in utero transplantation with fetal liver cells in a patient with X-linked severe combined immunodeficiency. American Journal of Obstetrics and Gynecology, 2002, 187, 475-482.	1.3	93
210	The TNFd4 allele is correlated to moderate-to-severe acute graft-versus-host disease after allogeneic stem cell transplantation. British Journal of Haematology, 2002, 119, 1133-1136.	2.5	43
211	Clinical tolerance after allogeneic hematopoietic stem cell transplantation. Transplantation, 2002, 73, 930-936.	1.0	8
212	The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. Blood, 2001, 98, 1982-1985.	1.4	87
213	Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation. British Journal of Haematology, 2001, 115, 935-944.	2.5	55
214	Polyclonal anti-T-cell globulin as part of the preparative regimen for pediatric allogeneic stem-cell transplantation. Pediatric Transplantation, 2001, 5, 285-292.	1.0	18
215	An ethnic role for chronic, but not acute, graft-versus-host disease after HLA-identical sibling stem cell transplantation. European Journal of Haematology, 2001, 66, 50-56.	2.2	17
216	T CELL MIXED CHIMERISM IS SIGNIFICANTLY CORRELATED TO A DECREASED RISK OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION 1. Transplantation, 2001, 71, 433-439.	1.0	88

#	Article	IF	Citations
217	TRANSPLANTATION OF AUTOLOGOUS AND ALLOGENEIC BONE MARROW WITH LIVER FROM A CADAVERIC DONOR FOR PRIMARY LIVER CANCER1. Transplantation, 2000, 69, 2043-2048.	1.0	30
218	Improved survival after bone marrow transplantation for early leukemia using busulfan-cyclophosphamide and individualized prophylaxis against graft-versus-host disease: a long-term follow-up. Clinical Transplantation, 1999, 13, 512-519.	1.6	15
219	RESULTS OF DIFFERENT STRATEGIES FOR REDUCING CYTOMEGALOVIRUS-ASSOCIATED MORTALITY IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS1. Transplantation, 1998, 66, 1330-1334.	1.0	150